Search

By Industry Solutions (2)
By Phase (1)
By Molecule Type (1)
By Therapeutic Area (3)
Covance Events (9)
Geography (3)
Keywords (10)

Filters

Showing results 113 - 128 of 91813 for .

Showing results 113 - 128 of 91813 for .

Why Supplement Manufacturers Are In a "New York State of Mind"
Makers of dietary supplements are keeping a close eye on New York after several major retailers were recently accused of selling mislabeled store-branded herbal supplements.
Evolving guidelines: a clearer flow cytometry strategy for drug development and clinical testing
Despite the growing use of flow cytometry, there are currently no official regulatory guidance documents governing its validation. Having recognized the gap, stakeholders from the pharmaceutical industry and clinical testing laboratories have proactively published recommendations.
Making Sense of Antisense Oligonucleotide-Based Therapies in Muscular Dystrophies
Good news for the Duchenne Muscular Dystrophy (DMD) community. On June 8th, BioMarin announced the filing of a Marketing Authorization Application to the European Medicines Agency for Drisapersen, an antisense-mediated exon 51-skipping compound able to target the most prevalent genetic mutations responsible for the lack of production of functional dystrophin.
Start at the Source: Five Steps to Improving Control of Your Infant Formula Supply Chain
Who do you trust with your brand? If you are not properly testing your raw materials, your brand's reputation may be at risk.
CDx: New Engine in a Classic Car
Companion diagnostics' impact on pharmaceutical development is like dropping a new engine into a classic car. Faster speed. Better performance.
Improve Clinical Trial Statistical Power With Proactive Data Pooling
To drive change, medicine requires hard data to supply evidence of clinical benefit.
The Remarkable Rebirth of Cancer Immunotherapy
There's reason for new hope in the ongoing battle against cancer. From standing-room-only presentations of provocative data at cancer conferences, to landmark publications and new drugs approvals, the signs are multiple and clear.
New Potentials in the Journey Ahead for Companion Diagnostics
Companion diagnostics are evolving quickly as novel technologies emerge and new drug targets appear. Dr. Mark Roberts, Director of Diagnostics Development, recently shared his thoughts on the industry trends ahead of the World CDx Boston 2015.
A New Level of Brand Protection: Five Things You Need to Know About PDE5 Inhibitor Adulterants
The adulteration of dietary supplements with synthetic phosphodiesterase type 5 (PDE5) inhibitors can cause serious adverse health risks.
How to Deal with Eligibility Creep in Immune-Mediated Inflammatory Disorders Studies | Part 1
Placebo response rates can obscure treatment effects, putting effective drugs at risk
Solving Culinary Challenges with Custom Study Solutions
I am a scientist, and sometimes my workspace is more like a kitchen. For over 30 years, I've led custom research studies for companies needing scientific evidence that their food products are safe. Often that means meticulously recreating food manufacturing processes in the lab.
Five Key Advances in Infectious Disease Drug and Vaccine Development
Infectious diseases contribute to approximately 25% of global mortality and present critical healthcare challenges, especially in under-resourced countries.
More Attention to Patients Can Increase Inflammation Study Effectiveness
Recent research contends some underlying immune system response mechanisms are common to inflammation-related diseases, such as asthma, COPD, psoriasis, rheumatoid arthritis, lupus and inflammatory bowel disease. These diseases are referred to as Immune-Mediated Inflammatory Disorders (IMIDs). There is a significant shift in the approach to managing traditional inflammatory diseases from organ-based symptom relief to tackling common underlying pathways of immune dysregulation which offers...
Vaccine and Novel Immunotherapeutic Development: A Personal Quest
Like my colleagues at Covance, my work ultimately contributes to improving Vaccine and Novel Immunotherapeutic Development Covance Bloghealthcare and patients' lives. Our efforts to accelerate fresh approaches towards effective treatments became deeply personal in 2007 when my oldest sister, Vicki, was diagnosed with advanced Triple Negative Breast Cancer (TNBC).
Vaccines and Immunotherapeutics: Three Ways to Improve Your Chances of Success
Advancing vaccine and novel immunotherapeutic development requires focused, specialized expertise. If you are looking to reveal more efficiencies in your vaccine and novel immunotherapeutic testing strategy, consider these three best practices...
Choosing the Best Pathway for CDx Development and Commercialization
Drug developers are increasingly incorporating a companion diagnostic (CDx) strategy into their programs to deliver safer, more effective and appropriate therapies to the right patients. While the end result can be significantly beneficial forCovance Labs CDx Drug Development and Commercialization patients, and development partners, the path from analytical and clinical validation to demonstrating clinical utility and obtaining regulatory approval is often challenging.